Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(2.34) per share which missed the analyst consensus estimate of $(2.21) by 5.69 percent. This is a 60.27 percent decrease over losses of $(1.46) per share from the same period last year.